Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Arginine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OTC | P00480 | 1/20 | 0.50 |
| ▸ | GSR | P00390 | 2/20 | 0.47 |
| ▸ | DDAH1 | O94760 | 3/20 | 0.47 |
| ▸ | NOS2 | P35228 | 6/20 | 0.45 |
| ▸ | NOS3 | P29474 | 5/20 | 0.45 |
| ▸ | NOS1 | P29475 | 5/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.42 |
| ▸ | APEX1 | P27695 | 1/20 | 0.42 |
| ▸ | GRM8 | O00222 | 1/20 | 0.41 |
| ▸ | GRM6 | O15303 | 1/20 | 0.41 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.41 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.41 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.41 |
| ▸ | GRM5 | P41594 | 1/20 | 0.41 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.41 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Arginine SCHEMBL26966738 | 1.00 | OTC (0.50) | OTCGSRDDAH1NOS2NOS3 | |
| Arginine SCHEMBL1533795 | 1.00 | OTC (0.50) | OTCGSRDDAH1NOS2NOS3 | |
| Arginine SCHEMBL536461 | 1.00 | OTC (0.50) | OTCGSRDDAH1NOS2NOS3 | |
| Arginine SCHEMBL8366388 | 1.00 | OTC (0.50) | OTCGSRDDAH1NOS2NOS3 | |
| Arginine SCHEMBL536977 | 1.00 | OTC (0.50) | OTCGSRDDAH1NOS2NOS3 | |
| Arginine SCHEMBL10619515 | 1.00 | OTC (0.50) | OTCGSRDDAH1NOS2NOS3 | |
| Arginine SCHEMBL8895106 | 1.00 | OTC (0.50) | OTCGSRDDAH1NOS2NOS3 | |
| Arginine SCHEMBL1445141 | 1.00 | OTC (0.50) | OTCGSRDDAH1NOS2NOS3 | |
| Arginine SCHEMBL536976 | 1.00 | OTC (0.50) | OTCGSRDDAH1NOS2NOS3 | |
| Arginine SCHEMBL27508634 | 1.00 | OTC (0.50) | OTCGSRDDAH1NOS2NOS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 113 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220154192-A1 | SYSTEM AND METHOD FOR LIGHT-REGULATED OLIGOMERIZATION AND PHASE SEPARATION OF FOLDED DOMAINS AND RNA GRANULE-ASSOCIATED PROTEIN DOMAINS FOR DRUG- BASED SCREENING APPLICATIONS | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2022-05-19 | — | — | US | claimed |
| EP-1399480-B1 | MULTIMERS OF CLASS I MAJOR HISTOCOMPATIBILITY COMPLEXES CONTAINING MODIFIED BETA2-MICROGLOBULIN PROTEINS | AVIDEX LTD (GB) | 2007-01-17 | — | — | EP | claimed |
| US-20240124878-A1 | COMPOSITIONS FOR AND METHODS OF ENGINEERING THE TRANSCRIPTOME | UNIV DUKE (US) | 2024-04-18 | — | — | US | disclosed |
| WO-2024065882-A1 | AMINO ACID-BASED WATER-BASED LIQUID, PREPARATION METHOD THEREFOR AND USE THEREOF | 中国科学院过程工程研究所 | 2024-04-04 | — | — | WO | disclosed |
| EP-4277987-A1 | COMPOSITIONS FOR AND METHODS OF ENGINEERING THE TRANSCRIPTOME | Duke University (US) | 2023-11-22 | — | — | EP | disclosed |
| US-20230295654-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF FRAGILE X SYNDROME | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2023-09-21 | — | — | US | disclosed |
| WO-2023135397-A1 | PROCESS FOR THE PREPARATION OF ANTIBODY-DRUG CONJUGATES | MC SAF (FR) | 2023-07-20 | — | — | WO | disclosed |
| WO-2023092075-A2 | COMPOSITIONS FOR AND METHODS OF TREATING AND/OR PREVENTING MALARIA | THE GEORGE WASHINGTON UNIVERSITY (US) | 2023-05-25 | — | — | WO | disclosed |
| EP-4181877-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF FRAGILE X SYNDROME | Children's Hospital Medical Center (US) | 2023-05-24 | — | — | EP | disclosed |
| WO-2023069923-A1 | COMPOSITIONS AND METHODS RELATING TO EPIGENETIC MODULATION | DUKE UNIVERSITY (US) | 2023-04-27 | — | — | WO | disclosed |
| US-20220154192-A1 | SYSTEM AND METHOD FOR LIGHT-REGULATED OLIGOMERIZATION AND PHASE SEPARATION OF FOLDED DOMAINS AND RNA GRANULE-ASSOCIATED PROTEIN DOMAINS FOR DRUG- BASED SCREENING APPLICATIONS | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2022-05-19 | — | — | US | disclosed |
| WO-1998031670-A1 | THROMBIN INHIBITORS | MERCK & CO., INC. (US) | 1998-07-23 | — | — | WO | disclosed |
| WO-1998002582-A9 | METHODS FOR DETECTING AND AMPLIFYING NUCLEIC ACID SEQUENCES USING MODIFIED OLIGONUCLEOTIDES HAVING INCREASED TARGET SPECIFIC T¿M? | — | 1998-05-28 | — | — | WO | disclosed |
| WO-1998002582-A2 | METHODS FOR DETECTING AND AMPLIFYING NUCLEIC ACID SEQUENCES USING MODIFIED OLIGONUCLEOTIDES HAVING INCREASED TARGET SPECIFIC T¿M? | GEN-PROBE INCORPORATED (US) | 1998-01-22 | — | — | WO | disclosed |
| WO-1997046266-A1 | IMPROVED BLOOD CONTACT SURFACES USING EXTRACELLULAR MATRIX SYNTHESIZED IN VITRO HAVING BIOACTIVE SPECIES IMMOBILIZED THERETO | GORE ENTERPRISE HOLDINGS, INC. (US) | 1997-12-11 | — | — | WO | disclosed |
| EP-0804460-A1 | CONFORMATIONALLY CONSTRAINED REVERSE-TURN LIBRARY AND METHODS RELATING THERETO | MOLECUMETICS, LTD. (US) | 1997-11-05 | — | — | EP | disclosed |
| WO-1996022304-A1 | CONFORMATIONALLY CONSTRAINED REVERSE-TURN LIBRARY AND METHODS RELATING THERETO | MOLECUMETICS, LTD. (US) | 1996-07-25 | — | — | WO | disclosed |
| US-RE31181-E | ARGININE | Kleinberg, Israel (US) | 1983-03-15 | — | — | US | disclosed |
| US-4225579-A | OLIGOPEPTIDE CONTAINING ARGININE | SANOFI S.A. (FR) | 1980-09-30 | — | — | US | disclosed |
| US-4154813-A | PEPTIDE HAVING TWO TO FOUR AMINO ACID GROUPS PLUS ARGININE | KLEINBERG ISRAEL | 1979-05-15 | — | — | US | disclosed |